增强简化急性生理评分II用于ICU死亡预测与基准比较:法国全国性研究
该法国全国性回顾性研究利用2015至2023年成人ICU住院数据(推导队列2 156 332例次)构建aug-SAPS II模型,并在2024年数据(242 465例次)中进行时间外部验证。aug-SAPS II在常规SAPS II基础上加入ICD-10衍生的Elixhauser合并症。推导队列中AUC从SAPS II的0.841(95%CI 0.840–0.841)升至aug-SAPS II的0.866(95%CI 0.865–0.866);验证队列中AUC分别为0.835(95%CI 0.833–0.837)和0.862(95%CI 0.860–0.864)。r-SAPS II和aug-SAPS II的校准均改善,医院水平随机效应方差在aug-SAPS II下降低28.7%。
要点
- 推导队列(2 156 332例次ICU住院)中,aug-SAPS II的AUC为0.866(95%CI 0.865–0.866),高于SAPS II的0.841(95%CI 0.840–0.841)。
- 验证队列(242 465例次住院)中,aug-SAPS II的AUC为0.862(95%CI 0.860–0.864),SAPS II为0.835(95%CI 0.833–0.837)。
- 校准方面,r-SAPS II和aug-SAPS II的校准-in-the-large从−1.10移至约0.00,校准斜率从0.72移至约1.00(医院水平和临床亚组均如此)。
- 验证队列中校准接近理想、SMR接近1;医院水平随机效应方差在r-SAPS II下不变,在aug-SAPS II下降低28.7%。
- aug-SAPS II仅使用常规收集的国家行政信息(人口学特征、SAPS II评分、ICD-10衍生的Elixhauser合并症),无需额外数据。
适用人群与场景
- 法国全国成人ICU住院患者,2015至2023年数据为推导队列,2024年数据为时间外部验证队列,2025年数据用于敏感性分析。
研究设计与关键结果
- 研究类型:法国全国性回顾性研究,使用法国国家住院数据库;推导队列2 156 332例次ICU住院,验证队列242 465例次住院。
- 干预/暴露:构建aug-SAPS II模型,在SAPS II基础上加入ICD-10衍生的Elixhauser合并症;同时评估r-SAPS II。
- 主要终点:判别度方面,推导队列AUC从SAPS II的0.841(95%CI 0.840–0.841)升至aug-SAPS II的0.866(95%CI 0.865–0.866);验证队列AUC从0.835(95%CI 0.833–0.837)升至0.862(95%CI 0.860–0.864)。
- 校准:r-SAPS II和aug-SAPS II的校准-in-the-large从−1.10移至约0.00,校准斜率从0.72移至约1.00(医院水平和临床亚组均如此);验证队列校准接近理想,SMR接近1。
- 医院间异质性:医院水平随机效应方差在r-SAPS II下不变,在aug-SAPS II下降低28.7%。
- 2025年数据敏感性分析结果一致。
证据类型、等级与局限
- 证据类型:全国性回顾性队列研究(使用行政数据库)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与原始SAPS II相比,aug-SAPS II改善了校准和判别度并降低了医院间变异,且无需额外数据 beyond 常规收集的国家行政信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severity scoring systems such as the Simplified Acute Physiology Score II (SAPS II) are widely used for benchmarking intensive care unit (ICU) performance, but their calibration deteriorates over time, leading to systematic overestimation of mortality in contemporary populations. We aimed to evaluate recalibrated SAPS II (r-SAPS II) and augmented SAPS II (Aug-SAPS II) models for mortality prediction using routinely collected national data. METHODS: This nationwide retrospective study used the French national database of hospital stays. Adult ICU stays from 2015 to 2023 constituted the derivation cohort; 2024 data were used for temporal external validation, and 2025 data for sensitivity analyses. Demographic characteristics, SAPS II score, and ICD-10–derived comorbidities defined according to the Elixhauser classification, were used to construct aug-SAPS II model. Model calibration was assessed using Cox calibration regression and standardized mortality ratios (SMRs), defined as the ratio of observed to predicted in-hospital deaths. Discrimination and between-hospital heterogeneity were quantified using the area under the receiver operating characteristic curve (AUC) and random-effects variance in SMRs from mixed-effects Poisson regression. RESULTS: In the derivation cohort (2 156 332 ICU stays), discrimination improved, with the AUC increasing from 0.841 (95% CI, 0.840–0.841) for SAPS II to 0.866 (95% CI, 0.865–0.866) for aug-SAPS II. Calibration improved for both r-SAPS II and aug-SAPS II, with calibration-in-the-large shifting from − 1.10 to approximately 0.00 and calibration slope from 0.72 to approximately 1.00 at both the hospital level and across clinical subgroups. In the validation cohort (242 465 stays), calibration remained close to ideal and SMRs were near 1; AUCs were 0.835 (95% CI, 0.833–0.837) for SAPS II and 0.862 (95% CI, 0.860–0.864) for aug-SAPS II. Hospital-level random-effects variance was unchanged with r-SAPS II but decreased by 28.7% with aug-SAPS II. Findings were consistent in 2025 data. CONCLUSIONS: Compared with the original SAPS II, aug-SAPS II improved calibration and discrimination and reduced between-hospital variability without requiring additional data beyond routinely collected national administrative information.
参考来源
- Kamel T, Boulain T. Augmenting the Simplified Acute Physiology Score II for intensive care unit mortality prediction and benchmarking: a French nationwide study. Crit Care. 2026. PMID: 41808194. doi:10.1186/s13054-026-05948-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。